Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders

doi:10.4254/wjh.v13.i12.1828

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 12

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8632)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

1071

WORD

213

HTML

5820

Figures (1-1)

274

Tables (1-2)

218

Sum=7596

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

378

Download

658

Sum=1036

Dec 27, 2021 (publication date) through Sep 18, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Dec 27, 2021; 13(12): 1828-1849
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.1828

Table 2 Management of patients with inflammatory bowel disease undergoing immunosuppressive therapy according to hepatitis B status

Hepatitis B status	Indications
HBsAg positive/anti-HBc positive (chronic hepatitis B)	Antiviral treatment (start 3-4 wk before and continue at least 12 mo after the immunosuppressive treatment)
HBsAg negative/anti-HBc positive (occult hepatitis B)	Liver function tests monitoring every 2-3 mo
HBsAg negative/anti-HBc negative/anti-HBs negative (naïve for hepatitis B)	Vaccination (indicated at diagnosis)
HBsAg negative/anti-HBc negative/anti-HBs positive	Check previous hepatitis B vaccination. Dose hepatitis B virus-DNA if uncertainty

HBsAg: Hepatitis B surface antigen.

Citation: Mazza S, Soro S, Verga MC, Elvo B, Ferretti F, Cereatti F, Drago A, Grassia R. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. World J Hepatol 2021; 13(12): 1828-1849
URL: https://www.wjgnet.com/1948-5182/full/v13/i12/1828.htm
DOI: https://dx.doi.org/10.4254/wjh.v13.i12.1828